- Home
- FNB vs MIRM Comparison
FNB vs MIRM Comparison
Compare FNB & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNB | MIRM |
|---|---|---|
| Founded | 1864 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FNB | MIRM |
|---|---|---|
| Price | $17.77 | $91.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $19.70 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 7.5M | 613.4K |
| Earning Date | 04-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | 22.83 | ★ 74.59 |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $14.12 | $26.22 |
| Revenue Next Year | $8.35 | $22.04 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.88 | $40.00 |
| 52 Week High | $19.14 | $109.28 |
Technical Indicators
Market Signals| Indicator | FNB | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 43.98 |
| Support Level | $17.38 | $85.35 |
| Resistance Level | $18.09 | $98.03 |
| Average True Range (ATR) | 0.40 | 3.31 |
| MACD | 0.01 | -0.57 |
| Stochastic Oscillator | 47.02 | 15.68 |
Price Performance
Historical ComparisonAbout FNB F.N.B. Corporation
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments, and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management, and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.